Arsenic Trioxide Targets miR-125b in Glioma Cells

2014 ◽  
Vol 20 (33) ◽  
pp. 5354-5361 ◽  
Author(s):  
Sulian Chen ◽  
Lihua Zhu ◽  
Jing Huang ◽  
Ying Cai ◽  
Xiaohui Lu ◽  
...  
2011 ◽  
Vol 104 (2) ◽  
pp. 449-458 ◽  
Author(s):  
Yaohua Liu ◽  
Yuan Liang ◽  
Tianhu Zheng ◽  
Guang Yang ◽  
Xu Zhang ◽  
...  

Oncogene ◽  
2004 ◽  
Vol 24 (6) ◽  
pp. 980-991 ◽  
Author(s):  
Takao Kanzawa ◽  
Li Zhang ◽  
Lianchun Xiao ◽  
Isabelle M Germano ◽  
Yasuko Kondo ◽  
...  

2017 ◽  
Vol 10 (1) ◽  
pp. 39
Author(s):  
Sehamuddin Galadari ◽  
Siraj Pallichankandy ◽  
Anees Rahman ◽  
Faisal Thayyullathil

2020 ◽  
Vol 25 (1) ◽  
Author(s):  
Yi Fang ◽  
Zhen Zhang

Abstract Arsenic trioxide has shown a strong anti-tumor effect with little toxicity when used in the treatment of acute promyelocytic leukemia (APL). An effect on glioma has also been shown. Its mechanisms include regulation of apoptosis and autophagy; promotion of the intracellular production of reactive oxygen species, causing oxidative damage; and inhibition of tumor stem cells. However, glioma cells and tissues from other sources show different responses to arsenic trioxide. Researchers are working to enhance its efficacy in anti-glioma treatments and reducing any adverse reactions. Here, we review recent research on the efficacy and mechanisms of action of arsenic trioxide in the treatment of gliomas to provide guidance for future studies.


2010 ◽  
Vol 116 (1) ◽  
pp. 183-193 ◽  
Author(s):  
Shin-Yi Liu ◽  
Ching-Ya Wen ◽  
Yi-Jang Lee ◽  
Te-Chang Lee

2020 ◽  
Author(s):  
Roshanak S. Sajjadi ◽  
Samaneh Ahmadi ◽  
Marziye Mantashloo ◽  
Sepideh Mehrpour Layeghi ◽  
Yazdan Asgari ◽  
...  

AbstractThe glioblastoma multiform has some properties including rapid growth, invasion, treatment resistance, and recurrence. Therefore, new therapies need to be developed that can be approved for using in patients. The previous study showed Arsenic Trioxide inhibits aggressive behavior in glioblastoma cells. Also, (–)-epigallocatechin-3-gallate prevents cellular proliferation, and invasion in multiple glioma cells. Resveratrol decreases cellular proliferation, induces cell death, and impaired the invasiveness of glioma cells. Combination therapy to inhibit cancer cells may have important clinical implications. Therefore, to assess the combination therapy of 2μM Arsenic trioxide, 100μM EGCG, and 100μM Resveratrol, we examined the metabolic activity, colony formation, media pH, cell proliferation, Caspase 3 activity, and gene expression analysis of BCL2, Caspase 3, MMP2, MMP9, CA9, u-PA, u-PAR, and Cathepsin B genes in apoptosis and invasion by both quantitative PCR experiments and Western blot assay. Systems biology tools also were used to obtain, the related network, involved pathways, and identifying the key genes in our selected criteria. The results of the study confirmed that the combined therapy prevents cell proliferation and induces of apoptosis in the Brain tumor cell lines including: U87-MG, A-172, and 1321N1. Furthermore, over-expression of caspase-3 and down-regulation of BCL-2, MMP-2, and MMP-9 confirmed that combination therapy leads to induces apoptosis and decreases invasion. Nevertheless, the lowering of pharmacological doses and improving therapeutic efficacy through combination therapy may provide advantages to treat resistance cancer cells with lower side effects. Finally, the results might suggest new modality for Glioblastoma treatment.


Sign in / Sign up

Export Citation Format

Share Document